1. National Organization for Rare Disorders (NORD). Pompe disease. 2021. https://rarediseases.org/rare-diseases/pompe-disease/. Accessed 1 May 2023.
2. Amicus Therapeutics Europe Limited. Pombiliti (cipaglucosidase alfa) 105 mg powder for concentrate for solution for infusion: EU summary of product characteristics. 2023. https://ec.europa.eu/health/documents/community-register/2023/20230320158375/anx_158375_en.pdf. Accessed 1 May 2023.
3. Schoser B, Roberts M, Byrne BJ, et al. Safety and efficacy of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in late-onset Pompe disease (PROPEL): an international, randomised, double-blind, parallel-group, phase 3 trial. Lancet Neurol. 2021;20(12):1027–37.
4. Meena NK, Raben N. Pompe disease: new developments in an old lysosomal storage disorder. Biomolecules. 2020;10(9):1339.
5. Amicus Therapeutics. Amicus Therapeutics announces European Commission approval for Pombiliti™ in patients with late-onset Pompe disease [media release]. 27 Mar 2023. https://ir.amicusrx.com/news-releases/news-release-details/amicus-therapeutics-announces-european-commission-approval-1.